• Vaccine Name: Flagrp170
• Target Pathogen: Cancer
• Target Disease: Cancer
• Vaccine Ontology ID: VO_0007604
• Type: engineered chimeric molecule
• Status: Research
• Antigen: gp100/PMEL and TRP2/DCT
• Preparation: Strategically incorporated a pathogen (i.e., flagellin)-derived, NF-κB-stimulating "danger" signal into the large stress protein or chaperone Grp170 (HYOU1/ORP150) that was previously shown to facilitate antigen crosspresentation. This engineered chimeric molecule (i.e., Flagrp170) is capable of transporting tumor antigens and concurrently inducing functional activation of dendritic cells (DC) (Yu et al., 2013).
• Immunization Route: Intramuscular injection (i.m.)

Human Response

• Vaccine Immune Response Type: VO_0003057
• Immune Response: The enhanced tumor destruction is accompanied with significantly increased tumor infiltration by CD8(+) cells as well as elevation of IFN-γ and interleukin (IL)-12 levels in the tumor sites (Yu et al., 2013).